NCT00809159 - Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Ankylosing Spondylitis

Interventions

BIOLOGICAL

AIN457

AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.

DRUG

Placebo

Placebo to AIN457

Trial Locations (20)

5800

Novartis Investigative Site, Maastricht

6231

Novartis Investigative Site, Meerssen

12200

Novartis Investigative Site, Berlin

16635

Novartis Investigative Site, Duncansville

22081

Novartis Investigative Site, Hamburg

22700

Novartis Investigative Site, Amsterdam

29406

Novartis Investigative Site, North Charleston

37909

Novartis Investigative Site, Knoxville

38305

Novartis Investigative Site, Jackson

44649

Novartis Investigative Site, Herne

62703

Novartis Investigative Site, Springfield

62704

Novartis Investigative Site, Springfield

73112

Novartis Investigative Site, Oklahoma City

76126

Novartis Investigative Site, Benbrook

85253

Novartis Investigative Site, Paradise Valley

99204

Novartis Investigative Site, Spokane

D-80639

Novartis Investigative Site, München

LS7 4SA

Novartis Investigative Site, Leeds

NE2 4HH

Novartis Investigative Site, Newcastle upon Tyne

OX3 7LD

Novartis Investigative Site, Oxford